Skip to main content
Figure 4 | Arthritis Research & Therapy

Figure 4

From: Long-term tolerability and maintenance of therapeutic response to sodium oxybate in an open-label extension study in patients with fibromyalgia

Figure 4

Maintenance of sodium oxybate therapeutic response in open-label extension study for patients with at least 12 months of sodium oxybate exposure ( n= 210). *SF-36 PCS is reported for weeks 14, 18, 38 and 42. FIQ, Fibromyalgia Impact Questionnaire; SEM, standard error of the mean; SF-36 PCS, 36-item short-form health survey physical component summary; VAS, visual analog scale.

Back to article page